(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of -29.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.55%.
Vir Biotechnology's revenue in 2026 is $303,227,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $42,285,375,745, with the lowest VIR revenue forecast at $39,623,608,725, and the highest VIR revenue forecast at $46,906,663,558. On average, 10 Wall Street analysts forecast VIR's revenue for 2027 to be $17,386,939,685, with the lowest VIR revenue forecast at $10,953,179,745, and the highest VIR revenue forecast at $29,335,278,479.
In 2028, VIR is forecast to generate $23,610,702,620 in revenue, with the lowest revenue forecast at $9,384,886,247 and the highest revenue forecast at $39,444,239,810.